GlassScriptPhysician profile
Odasy N Elejarde
NPI 1497228589
$5,116.84
in general payments reported to CMS, 2019-2025
27 companies · $467 in 2025
The $467 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,562 · 2022: $905 · 2023: $1,988 · 2024: $195 · 2025: $467.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,550 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,550.28 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $808.00 | 2021-2023 | Reblozyl, Onureg |
| Sanofi-Aventis U.S. LLC | $496.46 | 2021-2023 | |
| Janssen Biotech, INC. | $491.72 | 2021-2023 | Tecvayli, Carvykti, Darzalex |
| Astrazeneca Pharmaceuticals LP | $424.84 | 2021-2025 | Imfinzi, Imjudo |
| E.R. Squibb & Sons, L.L.C. | $392.27 | 2023-2025 | Reblozyl, Opdualag |
| Amgen INC. | $378.40 | 2021-2023 | Vectibix, Xgeva, Nplate |
| Daiichi Sankyo INC. | $337.83 | 2021-2024 | Vanflyta |
| Sobi, INC | $228.13 | 2022-2023 | |
| Seagen INC. | $224.99 | 2023-2025 | Adcetris |
| Lilly USA, LLC | $171.49 | 2021-2023 | Jaypirca |
| Eisai INC. | $168.53 | 2023 | |
| Coherus Oncology, INC. | $140.61 | 2021 | |
| Genzyme Corporation | $123.20 | 2023 | |
| Kyowa Kirin, INC. | $122.07 | 2021 | |
| Abbvie INC. | $119.90 | 2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $93.27 | 2023 | |
| Taiho Oncology, INC. | $81.90 | 2022-2023 | |
| Grifols USA, LLC | $61.51 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $54.20 | 2024-2025 | Onivyde, Somatuline Depot |
| Astellas Pharma US INC | $40.38 | 2023 | |
| Merck Sharp & Dohme LLC | $38.46 | 2021-2025 | Keytruda, Reblozyl |
| Incyte Corporation | $23.54 | 2023 | Monjuvi |
| Astellas Pharma Global Development | $21.55 | 2025 | Padcev |
| Stemline Therapeutics INC. | $19.74 | 2025 | Elzonris |
| Genentech USA, INC. | $18.92 | 2023 | Tecentriq, Rozlytrek, Gavreto |
| Exelixis INC. | $18.26 | 2025 | Cabometyx |
| Genmab U.S., INC. | $16.67 | 2025 | Tivdak |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Odasy Elejarde listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.